In a study by Neri et al., conducted on both B-pre-ALL cell lines and adult primary cells, RAD001 (everolimus), an mTORC1 inhibitor, used in combination with MK-2206 (an allosteric Akt inhibitor) or CCI-779 (another mTORC1 inhibitor) with GSK 690693 (an ATP-competitive Akt inhibitor), showed synergistic effects on the reduction of cell viability, cell cycle arrest in G0/G1, and induction of apoptosis and autophagy compared with the action of the individual drugs. The gene discussed is AKT1; the disease is acute lymphoblastic leukemia.